Prostate Cancer VL

Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy

Details
Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows high-risk adverse pathologic features (adjuvant radiotherapy) or if they experience biochemical recurrence (salvage radiotherapy). Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/A...

(TROG 08.03/ANZUP RAVES) Phase 3 Trial on Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen provide an in-depth review of the Lancet Oncology publication "Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial" in this UroToday Journal Club. Biographies: Christopher J.D. Wallis, MD, Ph.D., Instructor in Urology, Vanderbilt University...

The Relationship Between Surgeon Age and Post-Operative Outcomes - Raj Satkunasivam, Zachary Klaassen, Christopher Wallis

Details
In this Journal Club, Zachary Klaassen discusses a study on surgeon age with Raj Satkunasivam and Chris Wallis each an author on the paper titled, "Relationship Between Surgeon Age and Postoperative Outcomes, A Population-Based Cohort Study,” published in the Canadian Medical Association Journal. The surgical workforce, especially for urologists, is aging. This study aimed to determine whether pos...

Urinary Symptoms Post-Prostatectomy Case Study - Diane Newman

Details
Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents Urinary Symptoms Post-Prostatectomy Case Study of a 68-year old male with long-term lower urinary tract symptoms, treated for many years for BPH who had a robotic-assisted radical prostatectomy after being diagnosed with prostate cancer. Biographies: Diane K. Newman, DNP, ANP-BC, FAAN , Adjunct Professor of U...

Treating Post Prostatectomy Incontinence - Diane Newman

Details
Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents on one of the most challenging complications and an independent predictor of global quality of life, post-prostatectomy incontinence. Biographies: Diane K. Newman, DNP, ANP-BC, FAAN , Adjunct Professor of Urology in Surgery, Perelman School of Medicine, University of Pennsylvania and Co-Director of the Penn C...

Outpatient Trans-Rectal MR-Guided Laser Focal Therapy Phase II Clinical Trial: 10-Year Interim Results - John Feller

Details
John Feller presents at the Focal Therapy and Imaging in Prostate and Kidney Cancer Symposium, sharing interim 10-year results of the Phase II trial of Laser Focal Therapy for prostate cancer. This involves an outpatient trans-rectal laser therapy guided with an MRI imaging system. 95% of patients were biopsy compliant at 6 months and 94% avoided whole gland therapy and associated morbidity. The r...

Focal Therapy in Prostate Cancer - Art Rastinehad

Details
Prostate cancer survivor John Fortin is joined by Art Rastinehad a professor of urology and radiology at Mount Sinai to discuss targeted therapies for prostate cancer. Together they discuss when patients are recommended to active surveillance, versus when they must receive more complex treatment regimes. They discuss the research done to identify and test focal therapies for prostate cancer. Dr. R...

The Evolution of Care: Focal Therapy for Prostate Cancer: Tom Polascik

Details
Tom Polascik, a urologic oncologist with considerable experience in treating both kidney and prostate cancer and the founder of the Focal Therapy Society joins John Fortin providing a background of the Focal Therapy society and the 12th International Symposium on focal therapy and imaging in prostate and kidney cancer. He shares the concept of the society and summarizes the evolution of care in pr...

Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal

Details
In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...

Gold Nanoparticles Used in Photothermal Therapy for Prostate Tumors- Art Rastinehad

Details
(Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...